[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1b269f2b31a5e37ff6b2cd294b6638916e3ca2eea82c84072d601d793b15d190",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746808200,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "id": 134389609,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1b269f2b31a5e37ff6b2cd294b6638916e3ca2eea82c84072d601d793b15d190"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Numbers Came Up A Little Short’",
    "summary": "We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other Jim Cramer stocks with huge upside potential. During the episode of Mad Money aired on Wednesday, Jim Cramer broke down […]",
    "url": "https://finnhub.io/api/news?id=95bf7e6955d325d0e5bca7b5977665903688826456300a034df5c376adf2f665",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746802056,
      "headline": "Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Numbers Came Up A Little Short’",
      "id": 134362509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other Jim Cramer stocks with huge upside potential. During the episode of Mad Money aired on Wednesday, Jim Cramer broke down […]",
      "url": "https://finnhub.io/api/news?id=95bf7e6955d325d0e5bca7b5977665903688826456300a034df5c376adf2f665"
    }
  },
  {
    "ts": null,
    "headline": "1 Cash-Heavy Stock on Our Buy List and 2 to Ignore",
    "summary": "A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.",
    "url": "https://finnhub.io/api/news?id=be2c0e411492b7d266915ced35931a246dd429ec49a553d38452c4c88a502932",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746765470,
      "headline": "1 Cash-Heavy Stock on Our Buy List and 2 to Ignore",
      "id": 134336072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.",
      "url": "https://finnhub.io/api/news?id=be2c0e411492b7d266915ced35931a246dd429ec49a553d38452c4c88a502932"
    }
  }
]